Our pharmacogenomic analysis identifies TRIM2, FBXO44, and GLTPD2 as potential genetic modifiers, whose higher expression levels attenuate the deleterious effects of N06AX antidepressants on WMH burden, with GLTPD2 also reducing dementia risk. The gene discussed is FBXO44; the disease is dementia.